Oblique Therapeutics identifies epitope for SARS-CoV-2 antibodies

By The Science Advisory Board staff writers

June 11, 2020 -- Oblique Therapeutics has used its Abiprot antibody discovery platform to identify an epitope in SARS-CoV-2 that may facilitate the generation of new neutralizing antibodies to treat COVID-19.

Abiprot is based on a tailored molecular reporter system and proteomics. The system can identify high-affinity antibody binding sites in any given protein with single-amino acid resolution.

By working to map additional epitopes on the SARS-CoV-2 surface isolated from the nasal swab of a COVID-19 patient, the company identified the new epitope in a pilot study. The company will make all of the results freely available for vaccine and antibody-developing pharmaceutical and biotechnology companies.

The research to discover the epitope was conducted in collaboration with scientists from institutions in Sweden including Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, and Karolinska Institute with support from Nanoxis Consulting.

Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.
Alligator, Scandion pursue preclinical immunotherapies
Sweden-based Alligator Bioscience and Scandion Oncology inked an agreement to explore the antitumor efficacy of CD40 antibody mitazalimab in combination...
Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer...

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter